Inogen Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Inogen Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $348.67M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $335.71M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $315.66M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $377.24M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $358.00M | Mar 1, 2024 |
| FY2020 | Dec 31, 2020 | $73.98M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $74.33M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $71.69M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $88.49M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $78.92M | Feb 24, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $295.30M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $278.76M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $251.61M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $320.55M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $311.73M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $280.19M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $340.55M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $336.02M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $225.49M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $168.17M | Feb 26, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $225.49M | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $168.17M | Feb 27, 2018 |
| FY2017 | Dec 31, 2015 | $113.63M | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $73.10M | Feb 28, 2017 |
| FY2015 | Dec 31, 2013 | $44.91M | Mar 14, 2016 |
| FY2014 | Dec 31, 2012 | $28.70M | Apr 27, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.27M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $154.74M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $126.70M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $153.53M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $176.48M | Mar 1, 2024 |
| FY2020 | Dec 31, 2020 | $34.06M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $33.01M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $32.75M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $38.37M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $33.92M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.75M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($35.89M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($102.45M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($83.77M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | ($6.33M) | Mar 1, 2024 |
| FY2020 | Dec 31, 2020 | ($5.12M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($1.70M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $2.58M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | ($1.59M) | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | ($1.38M) | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($30.21M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($42.52M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($109.39M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($85.24M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.24M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($12.03M) | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $19.79M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $37.89M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $27.59M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $22.86M | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.40M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $21.61M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $20.84M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $21.94M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $16.58M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $14.08M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $9.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $7.03M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $5.31M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $5.11M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.22M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($3.23M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($37.53M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $23.63M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $37.01M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $40.59M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $59.98M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $60.49M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $31.03M | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.52M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.36M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $5.22M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $3.34M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $5.48M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $4.39M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $3.14M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $8.04M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.91M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.72M | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $298.63M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $296.19M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $326.19M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $405.04M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $489.51M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $461.85M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $447.34M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $375.90M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $275.07M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $214.05M | Feb 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.39M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $122.33M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $121.38M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $107.64M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $119.29M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $112.23M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $102.72M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $65.47M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $48.03M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $31.96M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $192.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $173.86M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $204.81M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $297.41M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $370.23M | Feb 28, 2025 |
| FY2023 | Dec 31, 2020 | $349.62M | Mar 1, 2024 |
| FY2022 | Dec 31, 2019 | $344.62M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $310.42M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $227.04M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $182.09M | Feb 25, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $9.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $10.06M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $32.85M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $32.98M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $33.17M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $32.95M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $2.26M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.36M | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($175.58M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($152.84M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($116.95M) | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | ($14.50M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $69.27M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $75.61M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $81.43M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $60.48M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $8.64M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($12.36M) | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.73M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $113.80M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $125.49M | Feb 27, 2026 |
| FY2023 | Dec 31, 2022 | $187.01M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $235.52M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $211.96M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $198.04M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $196.63M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $142.95M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $92.85M | Feb 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $315.0K | Mar 14, 2016 |
| FY2014 | Dec 31, 2014 | $614.0K | Apr 27, 2015 |
| FY2014 | Dec 31, 2013 | $10.65M | Apr 27, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 1, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | (4) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (3) | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 1, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.23M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 23.90M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 23.32M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 22.94M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 22.73M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 22.13M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 22.03M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 21.78M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 20.98M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 20.39M | Feb 27, 2018 |